AI Article Synopsis
- The study aimed to compare the effectiveness of continuous glucose monitoring (CGM) with continuous insulin infusion (CSII) against a degludec-based multiple daily injection (MDI) regimen in managing glucose levels in type 1 diabetes patients.
- The trial involved 28 participants who were randomly assigned to one of two treatment sequences, evaluating their glycemic control over time.
- Results showed that the CSII + CGM combination led to a greater reduction in HbA1c levels compared to MDI + SMBG, indicating that CSII + CGM is a more effective option for glucose control in type 1 diabetes.
Article Abstract
Aim: To investigate the efficacy of a combination of continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII) versus an optimized degludec-based multiple daily injections (MDI) regimen + self-monitoring of blood glucose (SMBG) in people with type 1 diabetes with regard to optimizing glucose control.
Material And Methods: The trial included 28 individuals who underwent a 4-week run-in phase, and were then randomized 1:1 to: (a) CSII + CGM followed by MDI + SMBG or (b) an MDI basal-bolus regimen followed by CSII + CGM.
Results: In patients randomized to the CSII + CGM → MDI + SMBG arm, a significant reduction in glycated haemoglobin (HbA1c) versus baseline was found at the end of the first phase (CSII + CGM) without significant variation in the following MDI + SMBG phase. In the arm randomized to the MDI + SMBG → CSII + CGM sequence, a significant improvement in HbA1c was observed in the first phase (MDI + SMBG), together with a further decrease in the following CSII + CGM phase. In the comparison of the two treatments using a mixed linear model, CSII + CGM was superior to MDI + SMBG with respect to change in HbA1c (P = 0.001).
Conclusions: This study suggests that CSII + CGM improves glycaemic control without relevant safety issues in type 1 diabetes, in comparison with MDI + SMBG.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dom.14028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutaneous Adverse Effects From Diabetes Devices in Pediatric Patients With Type 1 Diabetes Mellitus: Systematic Review.
JMIR Dermatol
November 2024
Rowan-Virtua School of Osteopathic Medicine, 113 Laurel Rd, Stratford, NJ, 08084, United States, 1 (856) 566-6789.
Article Synopsis
- Continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusions (CSII) are essential treatments for type 1 diabetes (T1D), but they may cause dermatologic complications like contact dermatitis and lipodystrophies, which negatively affect glycemic control and patient adherence.
- A systematic review analyzed 30 studies focusing on dermatologic issues related to CGM and CSII in pediatric patients, finding that contact dermatitis was the most common complication reported.
- The findings highlight the need for better manufacturer transparency and further research to address how these skin complications may impact long-term T1D management in young patients.
Diabetes remission in newly diagnosed type 2 diabetes mellitus through short-term continuous subcutaneous insulin infusion intensive therapy combined with low-carbohydrate diet treatment.
J Diabetes Investig
November 2024
Department of Nutrition, The First People's Hospital of Nanning, Nanning, Guangxi, China.
Aim/introduction: To evaluate the therapeutic efficacy short-term continuous subcutaneous insulin infusion (CSII) intensive therapy combined with a low-carbohydrate diet (LCD) for diabetes remission in patients with newly diagnosed type 2 diabetes mellitus.
Materials And Methods: This study included patients newly diagnosed with type 2 diabetes mellitus, who were randomly divided into two groups: conventional (conventional CSII + traditional lifestyle guidance); and intensive (intensive CSII + LCD lifestyle guidance). CSII was used for blood glucose control, with continuous glucose monitoring (CGM) used to monitor blood glucose levels.
Diabetes Control and Clinical Outcomes among Children Attending a Regional Paediatric Diabetes Service in Australia.
Nutrients
November 2024
Bathurst Rural Clinical School (BRCS), School of Medicine, Western Sydney University, Bathurst, NSW 2795, Australia.
Australian children with diabetes commonly struggle to achieve optimal glycaemic control, with minimal improvement observed over the past decade. The scarcity of research in the rural and regional Australian context is concerning, given high incidence rates and prominent barriers to healthcare access in these areas. We conducted a retrospective audit of 60 children attending a regional Australian paediatric diabetes service between January 2020 and December 2023.
View Article and Find Full Text PDFBeyond the insulin pump: Unraveling diabetes tech dependency.
Diabetes Res Clin Pract
November 2024
Campus Bio-Medico University of Rome, Italy; The Blizard Institute, St. Bartholomew's and the London School of Medicine, London, UK. Electronic address:
Article Synopsis
- - The last 20 years have seen significant advancements in technology for managing Type 1 diabetes (T1D), such as insulin pumps and Continuous Glucose Monitoring (CGM) systems, providing benefits like customizable settings and trend analysis for better lifestyle management.
- - While these technologies improve T1D management, there's a concern about potential overreliance and addiction to these devices among patients.
- - The review explores the multifaceted aspects of dependency on diabetes technology, emphasizing the need for self-management skills and strategies to handle unforeseen scenarios despite the benefits offered by these tools.
Patient-reported outcome measures in type 1 diabetes outpatient care.
Hippokratia
January 2024
Endocrinology Department, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Unlabelled: Background: Patient-reported outcome measures (PROMs) assess how individuals perceive the disease and its impact on quality of life, representing an important complement to the metabolic evaluation in type 1 diabetes mellitus (T1DM). This study aimed to assess the PROMs and their association with metabolic control.
Methods: A cross-sectional study of adults with T1DM was conducted in the outpatient Endocrinology department between October 2022 and May 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!